Shares of SummitTherapeutics (NASDAQ: SMMT) rocketed as high as 75.2% Monday, before settling into a 57.5% gain as of 1:27 PM EDT. Aa an early-stage biotech, a potential blockbuster drug would be ...
Instead of delivering two therapies, ivonescimab from SummitTherapeutics, IMM2510 from Instil Bio, and BNT327 from BioNTech are all bispecific antibodies that inhibit VEGF and the PD-1 checkpoint ...
Shares of SummitTherapeutics Inc. jumped more than 30% premarket on Monday after the biotech company released late-stage trial data showing that its experimental lung-cancer treatment topped ...